Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells | Zendy

Katrin Anne Becker | Zendy; Alexander Carpinteiro | Zendy; Markus Hoffmann | Zendy; Stefan Pöhlmann | Zendy; Johannes Kornhuber | Zendy; Erich Gulbins | Zendy

Open Access

Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells

Author(s) -

Katrin Anne Becker,

Alexander Carpinteiro,

Markus Hoffmann,

Stefan Pöhlmann,

Johannes Kornhuber,

Erich Gulbins

Publication year - 2021

Publication title -

star protocols

Language(s) - English

Resource type - Journals

ISSN - 2666-1667

DOI - 10.1016/j.xpro.2021.100356

Subject(s) - ex vivo , vesicular stomatitis virus , in vivo , virology , sphingolipid , medicine , pharmacology , nasal administration , ceramide , virus , immunology , biology , apoptosis , microbiology and biotechnology , biochemistry

This protocol enables the testing of drugs against infection of epithelial cells with SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), using pseudo-typed replication deficient vesicular stomatitis virus particles (pp-VSV) presenting the SARS-CoV-2 spike protein. After treating human volunteers with amitriptyline, an approved antidepressant and inhibitor of the acid sphingomyelinase, freshly isolated nasal epithelial cells were infected ex vivo and infection levels were quantified. This protocol offers the possibility to rapidly test the efficacy of potential drugs in the fight against COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research